$783 Million DEI Lifeline — NIH FORCED Backtrack

(DailyVantage.com) – Federal courts have forced the NIH to reopen the door to nearly $800 million in frozen DEI and gender-identity grants, reviving a fight over whether taxpayer-funded science should push ideology or stick to health research that serves all Americans.

Story Snapshot

NIH is reconsidering thousands of DEI- and gender-identity–related grants after losing in court, covering roughly $783 million in funding.
Trump-era directives had halted or terminated grants tied to DEI, “gender ideology,” vaccine hesitancy, and other contested topics.
A federal judge ordered more than 2,000 awards restored, and settlements now cover over 5,000 grants nationwide.
NIH has removed formal DEI requirements and signaled these reinstated grants will not be renewed under new priorities.

How Courts Forced NIH to Reverse Its DEI Funding Freeze

In early 2025, the returning Trump administration pushed NIH to stop pouring money into politicized DEI and gender-identity projects by issuing internal guidance that prohibited or downgraded funding for proposals in those categories. NIH followed suit by stalling review of new DEI-linked applications and terminating hundreds of active grants midstream, a rare step in federal science funding. Researchers, unions, and Democratic attorneys general quickly sued, arguing the terminations were unlawful, arbitrary, and ideologically motivated.

By June 2025, a federal judge in Massachusetts ruled the shutdown likely violated administrative law and ordered NIH to restore more than 2,000 already-awarded grants that had been abruptly cut. Appellate courts, including the First Circuit and ultimately the Supreme Court, reviewed the broader policy, with the high court signaling that the anti-DEI directives were problematic but limiting some of the financial remedies available to grantees. That mixed outcome set the stage for settlement talks between NIH and its critics.

What the NIH Settlement Means for Taxpayers and Researchers

On December 29, 2025, NIH and multiple plaintiff groups filed joint settlement agreements committing the agency to reconsider thousands of frozen, denied, or withdrawn grants using its standard scientific review process, without applying Trump-era anti-DEI criteria. The disputed pool covers roughly $783 million and more than 5,000 grants nationwide, including projects on transgender health, LGBTQ+ issues, vaccine hesitancy, environmental health, and workforce diversity. In exchange, the plaintiffs agreed to drop remaining legal claims over those funding decisions.

Settlement timelines now bind NIH to specific deadlines for acting on reconsidered grants, forcing the bureaucracy to move faster than usual. Non-competing renewals had to be decided by the filing date, while already peer-reviewed new awards face a mid-January 2026 deadline. Other applications must be resolved by mid-April or late July 2026, depending on review stage. Early reports from higher-education outlets indicate NIH has already approved hundreds of previously shelved applications and is processing the rest in “droves.”

Trump’s Policy Shift Away from DEI and the NIH’s New Priorities

While the settlement looks like a win for DEI advocates on paper, NIH leadership is making clear that the long-term direction is moving away from identity-driven research. Director Jay Bhattacharya has publicly stated NIH is “not interested in funding DEI anymore,” arguing these initiatives did not deliver better health outcomes for minority communities. He has also said DEI-linked grants restored under court order will not be renewed when their current terms end because they no longer align with NIH priorities.

Concrete policy changes back up that message. NIH has removed requirements for formal “Diversity Plans” and “Plans for Enhancing Diverse Perspectives” from its funding opportunities and has told applicants that any such plans already submitted will not factor into award decisions. The agency is also rewriting its inclusion policy to focus more narrowly on including women and members of racial or ethnic minority groups in studies, rather than broader equity or social-justice frameworks that became common under previous administrations.

The DEI Funding Fight and the Bigger Battle Over Government Power

The clash over NIH’s DEI portfolio highlights a deeper question many conservatives have asked for years: who decides what counts as legitimate science when Washington controls the purse strings? Trump’s directives attempted to pull federal health research back from projects that embedded contested social ideologies in grant criteria, but the sweep of the terminations—spanning LGBTQ+ health, vaccine hesitancy, and workforce diversity—gave opponents ammunition to argue the administration overreached and violated procedural rules. Courts largely accepted that critique on process, not ideology.

For readers frustrated with years of “woke” spending, the outcome is mixed. The courts forced NIH to temporarily reopen the DEI spigot for existing and pending grants, shifting hundreds of millions of dollars back into controversial lines of research. At the same time, the administration and NIH leadership have used the fight to justify stripping out DEI mandates going forward and resetting funding priorities toward less ideologically framed projects. Future renewals will be a key test of whether that promised course correction sticks.